背景(考古学)
医学
重症监护医学
化疗
胰腺癌
鉴别诊断
疾病
腺癌
选择(遗传算法)
癌症
普通外科
内科学
病理
历史
考古
人工智能
计算机科学
作者
Rafael Álvarez,Alfredo Carrato,Jorge Adeva,I. Alés,Susana Prados,Manuel Valladares,Teresa Macarulla,Andrés Muñoz,Manuel Hidalgo
标识
DOI:10.1016/j.ejca.2018.01.078
摘要
Development of hyperbilirubinaemia is common in patients with advanced pancreatic adenocarcinoma, both at diagnosis as well throughout disease evolution. For this reason, hyperbilirubinaemia determines chemotherapy treatment selection, and therefore it should be considered one of the most relevant conditions. There is very little evidence for the use of chemotherapy in this setting. This article summarises the main causes of hyperbilirubinaemia, how to treat them as well as their differential diagnosis. The current clinical evidence of the available drugs as well as the recommendations of use different combinations in the context of hyperbilirubinaemia are also reviewed.
科研通智能强力驱动
Strongly Powered by AbleSci AI